B. KOVAN Et Al. , "An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.," Cancer biotherapy & radiopharmaceuticals , vol.37, no.1, pp.17-22, 2022
KOVAN, B. Et Al. 2022. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.. Cancer biotherapy & radiopharmaceuticals , vol.37, no.1 , 17-22.
KOVAN, B., ÖZKAN, Z. G., DEMİR, B., Tuncman, D., IŞIK, E. G., Simsek, D., ... BÜYÜKKAYA, F.(2022). An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.. Cancer biotherapy & radiopharmaceuticals , vol.37, no.1, 17-22.
KOVAN, Bilal Et Al. "An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.," Cancer biotherapy & radiopharmaceuticals , vol.37, no.1, 17-22, 2022
KOVAN, Bilal Et Al. "An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.." Cancer biotherapy & radiopharmaceuticals , vol.37, no.1, pp.17-22, 2022
KOVAN, B. Et Al. (2022) . "An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.." Cancer biotherapy & radiopharmaceuticals , vol.37, no.1, pp.17-22.
@article{article, author={Bilal KOVAN Et Al. }, title={An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.}, journal={Cancer biotherapy & radiopharmaceuticals}, year=2022, pages={17-22} }